Do you think Comvita will involve price war with any other manuka honey brands? check up this:https://www.costco.com/CatalogSearch...d=manuka+honey
Printable View
Do you think Comvita will involve price war with any other manuka honey brands? check up this:https://www.costco.com/CatalogSearch...d=manuka+honey
Charlie Munger, investing genius and Warren Buffett's right-hand man, dies at age 99
Pinduoduo‘s market value surpasses Alibaba
PDD Holdings Inc - ADR/ temuAlibaba Group Holding Ltd - ADR/taobao/tmall/
Mkt cap 195.89B
JD.Com Inc
Mkt cap 190.45B
https://asia.nikkei.com/techAsia/PDD...in%20the%20U.S.
Mkt cap 43.46B
Dave always does a great sell job, his rave must have impressed the judges for these Awards
In BusinessDesk (and paid for by Comvita)
(NZX:CVT), the premium natural health and wellness products provider, proudly announces its significant achievement in winning the coveted Best Growth Strategy category at the annual Deloitte Top 200 Awards.
Comvita CEO David Banfield stated, "We’re thrilled to receive the Best Growth Strategy award at the Deloitte Top 200 Awards. This recognition is a testament to the hard work and dedication of the talented Comvita team, around the world and here at home in Aotearoa New Zealand, who’ve played a crucial role in driving our recent growth and success."
Comvita's consumer focus and transformation program, has a focus on sustainability, social and environmental impact and connection to its amazing founding philosophy nearly 50 years ago. This has resonated with discerning consumers in their key markets around the world and has enabled Comvita to achieve strong levels of growth. Looking ahead, Comvita remains on track to deliver its 2025 EBITDA target of c$50M (20%) as they celebrate their 50th year.
And CVT share price in 220’s ……if you forget about the couple on months at Covid onset time share price hasn’t been this low s for over 10 years
Must be a bargain ……
CVT share price on a roll lately ….up from recent low of 220 to 238 ….could be back to 3 bucks pretty soon.
Did think 220 was rather oversold
Punters must believe in that award winning growth strategy
Looking forward to Dave’s next rave ……possibly good news out of China
Share price still going up
But Dave needs to print a good story to keep momentum up
Another downgrade....
https://www.nzx.com/announcements/425571
Comvita Limited NZX:CVT is today providing a further trading update following completion of its first half FY24 trading (unaudited) and an update to its forecast full year result for the year ending 30th June 2024.
Today's trading update is driven by weaker near-term consumer sentiment in China, a customer change in the US and a non-cash FX translation loss. Encouragingly, market share in key markets of China and US have remained strong, and sales in the last 10 weeks' lead up to Chinese New Year show improving trends. Management remains committed to its strategic plan which has delivered three and a half years of consistent growth in line with market guidance, positioning the company well once normalised trading resumes.
Summary
• H1 FY24 Revenue was $103M, down 8.1% vs prior corresponding period (pcp)
• H1 FY24 EBITDA* (excluding ERP System) is expected to be $9.5M, down 32% vs pcp. Excluding a non-cash FX loss, the change would have been down 22% versus previous guidance expecting it to be down 20%
• FY24 Revenue is now expected to be $225M to $235M (previously $245M to $255M)
• FY24 Reported EBITDA (after ERP investment) is now expected to be $30M to $35M (previously $33M to $38M)
• Drivers: Driven by reduced consumer demand, most notably in Comvita's largest market, China, and a moderation in North American demand, coupled with a distribution change
• Gross Margin remained around 60%. Market share is stable or growing in key markets
• Impact on FY25 Plan: Comvita is focussed on returning to consistent growth once trading conditions normalise, and its plan for FY25 EBITDA of $50M remains feasible, subject to timing of restoration of a more stable trading environment
H1 FY24 update
Comvita will release its H1 FY24 results on 21st February 2024 (refer to Tuesday 30th January announcement).
Comvita’s unaudited revenue for the half year ending 31st December 2023 was $103M, a reduction of $8.6M vs pcp, with recent acquisition HoneyWorld™ contributing $6.8M in revenue. Thus, on a like for like basis, revenue excluding HoneyWorld™ fell by $14M (-12%) vs pcp, after adjusting for Comvita sales to HoneyWorld™ in pcp of $1.4M.
Comvita’s unaudited EBITDA for the period (after adding back its one-off investment in its ERP system) is expected to be $9.5M which is approximately 32% down vs pcp. Comvita had previously forecast EBITDA (after ERP) to be 20% down vs pcp. There were $1.2M non-cash FX adjustments at 31st December relating to the strengthening of the NZD in the month, which could not have been forecast in the November trading update. Excluding the FX impact above, EBITDA would have been materially within guidance of 20% down.
Comvita’s unaudited NPAT (Net Profit after Tax) for the period is expected to be a loss of $3.2M ($0.8M NPAT after ERP) compared to a profit of $4.2M in the prior period. Net debt at the half year was $85.8M and inventory $143M.
FY24 guidance update
Looking to the full year, given subdued consumption in China and North America, Comvita has revised its full year revenue range to between $225M and $235M, compared to November guidance of $245M and $255M. Reported EBITDA (after ERP investment) is now forecast to be between $30M and $35M, compared to November guidance of $33M and $38M.
Comvita has identified c$8M of operating expenditure savings that can be realised in the second half to support delivery of this forecast. These comprise variable marketing and sales costs, performance-related incentives and reduction of transformation investment. Comvita is forecasting an improvement in its net debt position and a reduction in inventory, which will support positive operating cashflows in H2.
Update on trading conditions
China revenue for the half year was $33M, down 19% on pcp. The China revenue slowdown was driven by macro-economic weakness, impacting the premium consumer category. Sales in China during November and December showed improvement towards a more stable trading pattern. Reflecting this, China market Q1 FY24 revenue was -26% vs pcp and Q2 revenue -15% vs pcp. Q2 FY24 lifted by 76% vs Q1 FY24, an improvement beyond usual seasonality of c50-60% quarter on quarter (QoQ).
Revenue in Rest of Asia improved 52% or $6.6M to $19.2M driven by strong growth in Korea of 13% to $8.6M and Singapore of growth of $5.7M. ANZ revenue improved by $1.2M or 7% to $19.3M.
Comvita uses retail store presence in Hong Kong SAR, Singapore and Korea as a lead measure for consumer demand in the region, including China and is pleased to report good sell out performance in all three markets.
North America revenue for the half year was $13M, down 37% on pcp. North America sales were impacted by the loss of one customer in one region, inflationary pressure on discretionary spend and a disproportionately strong first half in the pcp. Comvita is seeing improvement in sales in the Natural and Grocery channel in America and since Christmas has signed new additional distribution agreements in this market.
Management outlook
Comvita’s trading fundamentals during the period remain sound. Market share grew in key markets, pricing remained consistent and the gross margins that are integral to the delivery of its FY25 plan remained around 60%.
This gives the board and management confidence that the current performance is revenue related, short term in nature and will return to normal. Comvita has further reviewed its FY25 plan to deliver $50M EBITDA and has confidence that this can still be delivered. However, this is dependent on a return to normal trading conditions in both China and North America, the timing of which is uncertain. Comvita has reviewed independent market data showing forecast consumer spending strengthening in 2024 and thus expects a steady improvement in consumption through the second half.
Commenting, David Banfield (Group CEO) said “We remain confident that our business model, premiumisation of the Mānuka honey category and long-term investment in our brand, puts us in a strong position once macro-economic conditions stabilise. We continue to maintain or grow share in our core markets, and we see premium retailers in the US and Middle East turn to Comvita as the only brand committed to growing the category with two new high-quality partnerships confirmed for H2. We remain committed to deliver cost reductions in H2 to protect our earnings and are forecasting a further reduction of debt and inventory in H2 supported by positive operating cash flow.”
“After three and a half years of consistent performance growing both top and bottom-line in-line with our market guidance and strategic plan we are disappointed in this result, which reflects current trading conditions. The team and I are absolutely focused on doing everything possible to ensure a return to our pattern of consistent long-term growth”.
Good eh Bob but aniother good rave from Dave ….all bright and rosy when things come right
A few different profit measures mentioned but this is the one that matters -Comvita’s unaudited NPAT (Net Profit after Tax) for the period is expected to be a loss of $3.2M ($0.8M NPAT after ERP) compared to a profit of $4.2M in the prior period.